Introduction
The current European Society of Cardiology and European Society of Anaesthesiology non-cardiac surgery (ESC/ESA-NCS) guidelines recommend that a multidisciplinary team conference with participation of a cardiologist, a surgeon, and an anaesthesiologist assesses the risk, plans the timing of moderate-to high-risk NCS, and decides the strategy in relation to surgery. 1 As an aid for decision making, an ESC/ ESA-NCS risk classification has been elaborated. 1 The ESC/ESA-NCS classification aims to predict the risk of major adverse cardiac events (MACE) defined as cardiac death and myocardial infarction (MI) and divides surgery into three risk categories ( and a risk index, which originally was developed to estimate the probability of 30-day mortality. 2 Until now, the ESC/ESA-NCS score has not been validated as a predictor of 30-day MACE in a large contemporary clinical care cohort.
Methods
We conducted a cohort study based on patient-level record linkage of the Western Denmark Heart Registry (WDHR) and the Danish National Patient Register (DNPR) evaluating patients undergoing a surgical procedure between 1 and 12 months after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).
Study setting and population
All patients treated with a PCI procedure between May 2005 and January 2012 were identified using the WDHR. 3, 4 This registry assembles patient and procedural information from all coronary procedures performed at the three large PCI centres in Western Denmark (Odense University Hospital, Aarhus University Hospital, and Aalborg University Hospital) covering the region's population of approximately 3 million inhabitants, corresponding to 55% of the Danish population. 3 For each patient, the first PCI procedure performed during the study period was included as the index procedure. As >95% of the PCI procedures at our centres are performed using DES, patients treated with balloon dilation alone or with BMS were not included. The Danish Civil Registration System provides each citizen with a unique personal identification number at birth or immigration; we were thus able to collect individual-level linked information throughout the national and regional administrative registries. 5 Data from WDHR were linked with data from the DNPR to identify patients who required surgery within 12 months after their PCI. Patients requiring surgery < _30 days after the PCI procedure were excluded since these patients have a very high risk of adverse cardiac events compared with patients requiring surgery between 1 and 12 months after surgery. 4 The DNPR contains data on all Danish hospital admissions since 1977, including dates of hospitalization, outpatient visits, and discharge diagnosis/surgical procedures coded according to the International Classification of Diseases-10th Revision (ICD-10). The Danish National Health Service provides taxsupported health care, guaranteeing access to general practitioners and hospitals, and partial reimbursement for prescribed medications. This approach ensures a high coverage in the used registries. 6 Surgery was categorized as low-, intermediate-, or high-risk procedures according to the latest version of the ESC/ESA-NCS guidelines on NCS and could be performed in local, spinal, or general anaesthesia. 1 The ESC/ESA-NCS guidelines recommend that risk assessment is based on estimates of 30-day risk of MI and cardiovascular death after NCS. In this study, we excluded cardiac surgery, closed orthopaedic repositions, and non-invasive endoscopic procedures (but included endoscopy procedures with biopsy, polypectomy, adrenaline injection, etc).
Patient characteristics and event definitions
Baseline characteristics were retrieved from the WDHR and the Danish Register of Medical Product Statistics. Myocardial infarction within the first 30 days after surgery was defined by a primary or secondary discharge diagnosis (ICD-10 code I21 from DNPR). This definition of MI has a sensitivity of 94% and a specificity of 98%. 7 Definitions of cardiac death and NCS have been described previously. 4 Major adverse cardiac events was defined as MI and cardiac death within 30 days after NCS. The patient-related composite endpoint comprised mortality and MI.
Statistical analysis
Events were summarized as 30-day cumulative incidences and reported as counts (percentages To evaluate risk factors in DES treated patients, we used bivariate logistic regression models. When assessing the impact of time from index PCI to surgery, we dichotomized time from PCI to surgery [> _30 days-6 months and >6-12 months (reference)] for patients treated with DES.
Conditional logistic regression analyses were used to assess the risk of each ESC/ESA-NCS risk group. We further adjusted in a forward manner for age and gender (Model 1), and for age, gender, peripheral artery disease, and renal disease (Model 2). Statistical analyses were performed using Stata 13 (StataCorp, College Station, TX, USA) and SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). The study was approved by the Danish Data Protection Agency (J.no. 2012-41-0164).
Results
Among 22 590 DES-treated patients, 5157 (23%) underwent surgery within 12 months of the index PCI. Patients undergoing cardiac surgery (n = 399) and surgery within 30 days after PCI (n = 712) were excluded, yielding a total of 4046 patients meeting the inclusion criteria. The patients were categorized into ESC/ESA-NCS low-(n = 2945), intermediate-(n = 1014), and high-risk surgery (n = 87) groups. Baseline patient characteristics are presented in Table 2 .
Risk factors and adverse events after surgery
We evaluated the possible risk factors associated with adverse events among the patients treated with PCI and presents the univariate ORs in Table 3 . Age, gender, peripheral artery disease, and acute surgery were all associated with all-cause mortality and the combined endpoint of mortality and MI. Acute coronary syndrome (ACS) as indication for PCI was a predictor of cardiac death and MACE but not a predictor of all-cause mortality or the combined endpoint of mortality and MI. Renal disease was a strong predictor for all events.
Due to the small number of high-risk surgery procedures, intermediate-and high-risk surgery patients were pooled into one group. As compared with ESC/ESA-NCS low-risk score, a moderate-to high-risk score was a univariate predictor of cardiac death, all-cause mortality, MACE, and the combined endpoint of mortality and MI. Thus, renal disease and the ESC/ ESA-NCS classification were the only variables that predicted all four endpoints. Table 4 shows the risk of adverse events for each ESC/ESA-NCS risk group. For all endpoints, we demonstrated an incremental 30-day risk from low to moderate and further to high-risk ESC/ ESA-NCS risk groups. The risk differences were largest for endpoints including all-cause mortality. MACE rates were 0.6% for low risk, 1.2% for intermediate-risk, and 3.4% for high-risk surgery, which almost were in accordance with the expected <1%, 1-5%, and >5%. 1 The rates of the combined endpoint of mortality and MI were 1.5%, 4.6%, and 14.9%, respectively. A multivariate regression analysis, adjusted for age and gender, did not alter the results significantly ( Table 4 , Model 1). Additional adjustment for peripheral artery disease and renal disease, were performed for all-cause mortality, MACE and the combined endpoint of mortality and MI, and did not alter the ORs considerably ( Table 4 , Model 2).
Risk stratification of ESC surgery risk groups

Discussion
The current study evaluated the ESC/ESA-NCS classification in a large cohort of patients treated with DES implantation within a year prior to NCS. During the study period, the recommended DAPT duration was 12 months after PCI. Our study documented that the ESC/ESA-NCS classification predicts the risk of adverse events in these patients. For all assessed endpoints, we demonstrated an incremental risk of adverse events from low-to moderate risk, and a further increase in high-risk surgery. Our study thus validates the ESC/ ESA-NCS classification as a tool for prediction of not only MACE, but also of cardiac death, all-cause mortality, and the combined endpoint of mortality and MI.
The ESC/ESA-NCS classification as a predictor of adverse events
The ESC/ESA-NCS classification is based on a risk index derived to estimate 30-day mortality after NCS. 1, 2 In the ESC/ESA-NCS guidelines, the risk of MACE following different NCS procedures was estimated to be either low (<1%), intermediate (1-5%), or high (>5%) depending on the type of surgery. 1 In our study, the corresponding rates for low-, intermediate-, and high-risk ESC/ESA-NCS were 0.6%, 1.2%, and 3.4%, respectively. Although our data do not match the ESC guidelines estimates perfectly, the incremental risk from low-to high-risk procedures for all endpoints substantiate our validation of the ESC/ESA-NCS classification. Prior stent implantation has been associated with a higher risk of adverse events than among patients without previous PCI and this risk is reduced over time. 8, 9 As such, our cohort consisting of DES-treated patients undergoing surgery within one and twelve months after PCI may be considered a highrisk cohort. The ESC/ESA-NCS classification aims to predict MACE. Although we confirmed an association, we found that the risk differences observed for all-cause mortality and the combined endpoint of mortality and MI were much larger than for MACE.
We evaluated the impact of several patient-related risk factors that may be associated with the surgical risk of a patient with IHD. Age, gender, ACS at the time of PCI, acute surgery, peripheral artery disease, and renal disease were all associated with an increased risk of one or more of the reported endpoints. On the contrary, diabetes, surgery between 1 and 6 months after PCI, and the remaining comorbidities in the modified CCI did not significantly impact adverse events. In a study by Hawn et al., 10 age, acute surgery, MI within the past 6 months prior to surgery, congestive heart failure in the past 6 months (not included in our analysis), and renal disease were found to be predictors of MACE, i.e. a finding very similar to ours. Renal disease is also incorporated in the Lee risk index 11 and the American College of Surgeons National Surgical Quality Improvement Program (NSQIP), 12 which both incorporate additional clinical risk factors and are recommended for cardiac perioperative risk stratification in the ESC/ESA-NCS guidelines. 1 This highlights that several factors must be considered at multidisciplinary team conferences prior to surgery, and that the ESC/ESA-NCS score, the Lee index, 11 and the NSQIP model 12 should be considered as pieces of the puzzle, in concert with the more traditional clinical information, when decisions on management strategy are taken.
Limitations
A strength of our study is cross-linking of national Danish registries, which enabled us to evaluate consecutive patients in a large real-world cohort. All patients had been treated with DES within 12 months prior to NCS. The latter suggests that this cohort, a priori, was a cardiovascular high-risk cohort due to recent PCI, a large proportion of recent ACS, and with a recommendation for dual anti-platelet therapy. The external validity must thus be expected to be high albeit not necessarily comparable to patients beyond 12 months of PCI, or to patients with medically or surgically treated coronary artery disease. We excluded patients undergoing NCS within the first month after stenting as surgery in this period was associated with a higher risk in the PCI cohort as compared to the background population. 4 We used a broad registry-based definition of cardiac death that has previously been used. 13, 14 Cardiac death was relatively rare as compared to all-cause mortality. At least to some degree, this likely represents a greater likelihood of physicians to classify a death based on the comorbidities indicating surgery. It may also be caused by confounding by indication, in this cohort a potentially greater likelihood of delaying or avoiding surgery due to recent ACS or dual antiplatelet therapy, leading to a 'healthy-patient' bias. Taking these limitations of retrospective registry-based detection of cardiac death into consideration, it is important to emphasize that cardiac death and all-cause mortality showed the same tendency.
Conclusions
The ESC/ESA-NCS classification is a valid tool to predict the risk of cardiac death, all-cause mortality, MACE, and the combined endpoint of mortality and MI within 30 days after NCS.
Conflict of interest: none declared.
